Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Yu Mi Kang (Kang YM), Chang Hee Jung (Jung CH)
Endocrinol Metab. 2016;31(2):258-274.   Published online 2016 Apr 25     DOI: https://doi.org/10.3803/EnM.2016.31.2.258
Citations to this article as recorded by Crossref logo
Changing Fields-Diabetes Medications Invading the Cardiovascular Space
Lauren D. Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P. Shah, Brandon E. Cave
Current Problems in Cardiology.2021; 46(3): 100736.     CrossRef
PEGDA/HA mineralized hydrogel loaded with Exendin4 promotes bone regeneration in rat models with bone defects by inducing osteogenesis
Wei Liu, Xiaowei Jing, Zhiwen Xu, Chong Teng
Journal of Biomaterials Applications.2021; 35(10): 1337.     CrossRef
PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice
Marie K. Holt, Daniel R. Cook, Daniel I. Brierley, James E. Richards, Frank Reimann, Alexander V. Gourine, Nephtali Marina, Stefan Trapp
Molecular Metabolism.2020; 39: 101024.     CrossRef
A glycosylated Fc ‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang, Young Chul Sung
Diabetes, Obesity and Metabolism.2020; 22(8): 1455.     CrossRef
Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials
Elodie M. Varin, Brent A. McLean, Julie A. Lovshin
Canadian Journal of Diabetes.2020; 44(1): 68.     CrossRef
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi, Manfredi Rizzo
Metabolism.2020; 111: 154343.     CrossRef
GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
Lili Zhang, Jiali Tian, Sujuan Diao, Guowei Zhang, Mochao Xiao, Dong Chang
Chemico-Biological Interactions.2020; 332: 109252.     CrossRef
Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Alina Yu. Babenko, Daria A. Savitskaya, Yulia A. Kononova, Aleksandra Yu. Trofimova, Anna V. Simanenkova, Elena Yu. Vasilyeva, Evgeny V. Shlyakhto
Journal of Diabetes Research.2019; 2019: 1.     CrossRef
Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
Ekaterina V. Tikhonenko, Alina Y. Babenko, Evgeny V. Shlyakhto
Obesity and metabolism.2019; 15(4): 22.     CrossRef
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
Diabetes & Metabolism Journal.2019; 43(4): 410.     CrossRef
Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
Camilla Krizhanovskii , Anders Franco-Cereceda
Current Vascular Pharmacology.2019; 17(5): 432.     CrossRef
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Gül Bahtiyar, Jean Pujals-Kury, Alan Sacerdote
Current Diabetes Reports.2018;[Epub]     CrossRef
Efficacy From Strange Sources
Lawrence J. Lesko
Clinical Pharmacology & Therapeutics.2018; 103(2): 253.     CrossRef
Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury
Lishuai Feng, Jianbo Wang, Xu Ma
Biomedicine & Pharmacotherapy.2018; 103: 290.     CrossRef
Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation
Wojciech Garczorz, Enrique Gallego-Colon, Agnieszka Kosowska, Agnieszka Kłych-Ratuszny, Michał Woźniak, Wiesław Marcol, K.J. Niesner, Tomasz Francuz
Cardiovascular Therapeutics.2018; 36(2): e12317.     CrossRef
Molecular and clinical roles of incretin-based drugs in patients with heart failure
Bassant Orabi, Rasha Kaddoura, Amr S. Omar, Cornelia Carr, Abdulaziz Alkhulaifi
Heart Failure Reviews.2018; 23(3): 363.     CrossRef
The effects of Exendin-4 on bone marrow-derived mesenchymal cells
Paola Luciani, Benedetta Fibbi, Benedetta Mazzanti, Cristiana Deledda, Lara Ballerini, Alessandra Aldinucci, Susanna Benvenuti, Riccardo Saccardi, Alessandro Peri
Endocrine.2018; 60(3): 423.     CrossRef
Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic
David M. Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, Win L. Yin, Richard Chudleigh, Stephen C. Bain, David E. Price, Jeffrey W. Stephens
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2018; 12(6): 1079.     CrossRef
Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
Maja Ðanić, Bojan Stanimirov, Nebojša Pavlović, Svetlana Goločorbin-Kon, Hani Al-Salami, Karmen Stankov, Momir Mikov
Frontiers in Pharmacology.2018;[Epub]     CrossRef
Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
Andrew J. Krentz, Gerardo Rodriguez-Araujo
Pharmaceutical Medicine.2017; 31(6): 399.     CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Rafael Simó, Cristina Hernández
Diabetes.2017; 66(6): 1453.     CrossRef
GLP-1 receptor agonists and heart failure in diabetes
André J. Scheen
Diabetes & Metabolism.2017; 43: 2S13.     CrossRef
Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
Yu Mi Kang, Chang Hee Jung
Endocrinology and Metabolism.2017; 32(3): 316.     CrossRef
Historique des études cardiovasculaires : de l’UGDP… aux dernières études
A.-J. Scheen
Médecine des Maladies Métaboliques.2017; 11: 2S15.     CrossRef
Cardiovascular safety and benefits of GLP-1 receptor agonists
Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll, Filip K. Knop
Expert Opinion on Drug Safety.2017; 16(3): 351.     CrossRef